Navigation Links
Pharmacyclics Announces Presentations and Published Abstracts on,Xcytrin at The 2007 American Society of Clinical Oncology Annual,Meeting

SUNNYVALE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today multiple presentations and a published abstract regarding Xcytrin(R) (motexafin gadolinium) Injection, including an oral presentation of Phase 3 SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial data. The presentations and publications are part of the proceedings at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO) that will be held June 1-5, 2007, at McCormick Place in Chicago, IL.

    The presentations and published abstracts are as follows:


    Sunday, June 3, 2007

    Session: Central Nervous System Tumors

    Oral Presentation: Motexafin gadolinium (MGd) combined with whole brain

    radiation therapy prolongs time to neurologic progression in non-small

    cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis

    of two randomized phase III trials. Abstract #2010: 3:00 - 3:15 p.m.


    Location: S100a

    Presenter: William Shapiro, M.D., Barrow Neurological Institute,

    Phoenix,AZ


    Session: Central Nervous System Tumors


    Poster Presentation: Identification of occult brain metastases amenable to

    stereotactic radiosurgery by motexafin gadolinium (MGd) based treatment

    planning MRI: Results of a phase II trial of MGd and whole brain

    radiotherapy (WBRT) with stereotactic radiosurgery (SRS).

    Abstract #2037: 8:00 a.m. - 12:00 p.m.;

    Discussion: 11:00 a.m. - 12:00 p.m.


    Poster Display Location: S102a; Discussion: S100a

    Presenter: Minesh P. Mehta, M.D., University of Wisconsin


    Motexafin Gadolinium Published Abstract

    Abstract #18001

    Title: A phase II trial of motexafin gadolinium (MGd) in advanced

    non-small-cell lung cancer (NSCLC) patients who had failed platinum-based

    chemotherapy: Preliminary results of Stage 1

About Xcytrin

Pharm acyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox-active drug that has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress related proteins. Its multifunctional mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R), has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc.

Web site: http://www.pharmacyclics.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Licenders is bringing their 100% all-natural lice removal service to ... at 203 13 th Street was specifically chosen to make ... "Our goal is to ease parents, stress and bring their ... children right back to class without skipping a beat. The best ... for the whole family," Licenders President Adie Horowitz states. ...
(Date:12/6/2016)... 6, 2016  "Blood Tests replace Surgical Biopsies. ... The Diagnostic, Monitoring and Screening Test opportunities ... is occurring using in vitro blood testing to ... impressive backing, has announced a single blood test ... faster than the market. New technology that definitively ...
(Date:12/6/2016)... 2016 Diabetes & Obesity Drug Development Pipeline ... disease cluster is currently dominated by therapeutics indicated for ... mellitus (T2DM), and the majority of the pipeline, in ... attributable to these indications. While products indicated for obesity ... are a large number of these products in the ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... ... December 07, 2016 , ... OC87 Recovery Diaries ... schizophrenic mother in a unique, personal perspective through animation. , That woman ... addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, lived with schizophrenia. ...
(Date:12/7/2016)... ... 2016 , ... Castle Dermatology Institute is now offering liquid facelifts with ... appearance to the face. Dr. Peyman Ghasri and Dr. Pedram Ghasri, San Fernando ... to rejuvenate and renew the facial appearance. , Sculptra is a highly effective ...
(Date:12/7/2016)... ... 07, 2016 , ... When it came time to blow out his candles on his 14th ... Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family with ... 30th heart transplant recipient. , “He was playing at home, when we got the ...
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... offering insurance and financial planning services to families and business owners in the ... funds on behalf of the Dallas Fallen Officer Foundation. , Established in 2009 ...
Breaking Medicine News(10 mins):